SBFI-26

Catalog No.S9957 Batch:S995701

Print

Technical Data

Formula

C28H22O4
Molecular Weight 422.47 CAS No. 1541209-75-9
Solubility (25°C)* In vitro DMSO 84 mg/mL (198.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO Corn oil
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

SBFI-26 competitively inhibits the activities of FABP5 and FABP7.
Targets
FABP5 [1] FABP7 [1]
In vitro

SBFI26 interferes with the FABP5-PPARγ- signalling pathway at the initial stage of the signal transduction by binding competitively to FABP5 to inhibit cellular fatty acid uptake. This avoids the fatty-acid stimulation of PPARγ and prevents it activating the downstream regulated cancer-promoting genes.<sup><a class="sref" href="#s_ref">[3]</a></sup>
In vivo

SBFI-26 produces analgesic effects by inhibiing the peripheral expression of FABPs in Complete Freund’s adjuvant(CFA)-treated mice.<sup><a class="sref" href="#s_ref">[2]</a></sup>

Protocol (from reference)

Cell Assay:

<sup><a class="sref" href="#s_ref">[3]</a></sup>
  • Cell lines

    PNT2, DU145, PC3, PC3-M, 22RV1, LNCaP

  • Concentrations

    25–125 μM

  • Incubation Time

    24 h

  • Method

    PC3-M cells (5 × 10<sup>4</sup>) are plated in triplicate in 96 well plates and incubated overnight. Cells are treated with different concentrations of SBFI26 (25–125 μM) for 24 h. And then Cell viability is assessed using MTT assay. Wound healing migration assay is carried out to evaluate the effect of SBFI26 on the migratory rate of PC3-M cells. Crystal violet staining is used for Invasion assay.
Animal Study:

<sup><a class="sref" href="#s_ref">[2]</a></sup>
  • Animal Models

    Complete Freund’s adjuvant model male C57Bl/6 mice

  • Dosages

    250 mg/kg

  • Administration

    i.p.

Selleck's SBFI-26 has been cited by 1 publication

Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma [ World J Clin Oncol, 2024, 15(1):130-144] PubMed: 38292656

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.